Correction to: Use of MFM-20 to monitor SMA types 1 and 2 patients treated with nusinersen.
Le Goff L, Seferian A, Phelep A, Rippert P, Mathieu ML, Cances C, de Lattre C, Durigneux J, Gousse G, Vincent-Genod D, Ribault S, Gómez García de la Banda M, Quijano-Roy S, Sarret C, Servais L, Vuillerot C.
Le Goff L, et al. Among authors: rippert p.
Neurol Sci. 2023 Mar;44(3):1139. doi: 10.1007/s10072-022-06522-w.
Neurol Sci. 2023.
PMID: 36418612
Free article.
No abstract available.